< Key Hightlight >

MARKET OUTLOOK

According to Triton Market Research, the North America infertility testing and treatment market is anticipated to garner a CAGR of 10.00% through the years 2021-2028. The United States and Canada together form the market in this region.

The studied market’s growth in Canada is owing to multiple factors, such as rising cases of STDs and a surge in obesity levels. Moreover, as per estimates, the infertility count is growing at a rapid pace across the country, influencing the need for infertility treatments. Furthermore, the supportive government measures to encourage infertility treatment, in addition to growing awareness about these treatments, are creating new opportunities for fertility clinics. For instance, the LIFE program was the first program introduced for treating infertility using in-vitro fertilization (IVF). Thus, such development indicates a robust growth of the infertility testing and treatment market within Canada. 

The increasing number of infertility cases in the United States, on account of the rising middle-age pregnancies and the declining fertility rates, primarily fuel the country’s infertility testing and treatment market growth. In addition, as a widely utilized treatment, it enables and assists single mothers, couples with infertility issues, as well as the LGBT community to procreate. Furthermore, factors such as the augmenting trend of delayed pregnancies, the growth in disposable income, and the surge in IVF success rates are expected to play a vital role in facilitating the demand for infertility testing and treatment in the United States.

COMPETITIVE OUTLOOK

The key companies in the infertility testing and treatment market are Create Fertility Centre, Fujifilm Irvine Scientific, Progyny, Olympus Corporation, Genea Ltd, Labotect GmbH, and Ferring Pharmaceuticals.